If you can’t You don’t
handle me deserve me at
at my worst my other worst

One of my patients (who labels himself a #PriorAuthSurvivor ) diagrammed the unnecessary complexity of trying to get his medication approved on time 👇

Rinse & repeat and this is a cyclic nightmare that has nothing to do with chemo but rather the bureaucracy of US healthcare

Day 3: #ethiopia Getting our day going with #goglobal co-chair & 2023 @sages_updates #internationalambassador Dr. M. Bailez! And a big #thankyou to the Alert Hospital officer team! #addisababa #teamwork #leadership #globalsurgery #addisababa #some4pedsurg #some4surgery

Day 1: Pre- COSECSA Congress #surgical #training set- up day at the Alert Hospital in #addisababa #goglobal #laparoscopy #globalsurgery #simulation #education #ethiopia #africa #some4pedsurg #some4surgery#glap #fls #fundamentals #bscmanagement #jqglobal

Day 2: GLAP & FLS kicking off #ethiopia ! First group of participants are out of the gate. #addisababa #laparoscopy #globalsurgery #fundamentals #safesurgery #some4pedsurg #some4surgery #sages_updates @samkatem20 Maria Marcela Bailez lauren

when I ask the medical student a question and the resident behind me is trying to give them the answer

why they made king size beds #CorgiCrew #CorgiRoyalty

In patients w/ cardiovascular disease & overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8 mos. Full SELECT trial results: nej.md/465pj91

#AHA23 AHA Science

Maximum dosage of #Semaglutide reduces MACE - cardiovascular events by 20% in people with #obesity - withholding insurance coverage for this medication for people with obesity is discriminatory #AHA23 #AHA2023

9% weight loss by semaglutide in the #SELECT trial led to significant cardiac benefits.

#AHA2023 #AHA23

FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems | Eli Lilly and Company - obesity #zepbound investor.lilly.com/news-releases/…

We approved a new injection for chronic weight management in adults with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes or high cholesterol), to use in addition to a reduced calorie diet and increased physical

#Zepbound is expected to be available in the U.S. by the end of the year in six doses at a list price of $1,059, which is approximately 20% lower than semaglutide 2.4 mg injection for #weight loss.

investor.lilly.com/news-releases/…

🚨Our longterm results from prospective cohort study at #mcgillbariatrics comparing #SADI vs #DS . At 5y f/u, #SADI has ↔️ wtloss & comorbidity improvements (esp T2D), however ⬇️ nutri def (esp ⬇️fat-soluble vit def) & GI symptoms (⬇️BMs/d) vs #DS . Obesity Surgery Journal IFSO

Was a “ruff” day at the “pawffice.” #CorgiCrew

lol who did this

This was a low-cost laparoscopic inguinal hernia repair that we were able to do without expensive equipment. We secured the mesh using only 2 sutures, both cut long so that we could use them for multiple intracorporeal throws. Go Team LapNamibia!!! 👏🏻🤩💪🏾 SAGES Is In Cleveland 2024! #GLAP

#goglobal #glap kicking Welcome to the team #namibia & #elsalvador ! Looking forward to your expansion team #hospitalcivildeguadalajara #mexico . Amazing #teamwork and new multi-committee #collaborations with team #costarica . Thank you to all our faculty🇺🇸🇧🇷🇦🇷🇨🇷🇺🇬🇳🇦🇲🇽

Asking Bariatric Surgeons if AOMs are “hurting business” is like asking Cancer Surgeons if chemotherapy is hurting business.

OBESITY IS A DISEASE. It requires both surgical and nonsurgical treatment. Sometimes one or the other, often times BOTH.

Imaging lymph node regression can predict the pathological tumor regression grade in gastric cancer after neoadjuvant treatment - SURGERY Journal surgjournal.com/article/S0039-…